| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 18, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
EFFECT - ANEW Medical, Inc. (0001907223) (Filer)
S-1 - ANEW Medical, Inc. (0001907223) (Filer)
8-K - ANEW Medical, Inc. (0001907223) (Filer)
4 - ANEW Medical, Inc. (0001907223) (Issuer)
3 - ANEW Medical, Inc. (0001907223) (Issuer)
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ:WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ:KLTO), and has launched a new website, www.klothoneuro.com. The name and ticker change will have no impact on current shareholders, and there is no action required on their part. The new name embodies the Company's commitment to strategically direct its core investments of time and financial resources toward the multibillion-dollar market opportunities for the company's patented Klotho gene technology assets in the neurosciences sector. Through its exclusive worldwide license, the company's patent protected secr
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development. One is to enhance the potential of people achieving a healthy long life, and the other is the development of effective treatments for age-related disorders and neurodegenerative diseases such as ALS, Alzheimer's and Parkinson's disease. ANEW has secured exclusive worldwide rights and issued patents in the USA, Canada, Europe, Hong Kong and China, covering the secreted form of Klotho, known scientifically as s-KL. Klotho is often referred to as "the anti-aging gene." It is named after the
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ:WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors. This strategic move significantly strengthens ANEW's balance sheet by eliminating over $4 million in long-term debt. The elimination of over $4 million in long-term debt not only clears ANEW's balance sheet but also significantly increases stockholder equity, positioning the company for future growth and investment opportunities. It also eliminates $600,000 in annual interest payments owed by the company. The avera
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (NASDAQ:WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of Jeffrey LeBlanc as the company's Chief Financial Officer (CFO), replacing the interim CFO, Edward Cong Wang who was the former CFO of Redwoods Acquisition Corp into which ANEW merged. "Jeff LeBlanc is a highly experienced senior executive, and we are absolutely delighted to welcome him to our team," commented, Dr. Joseph Sinkule, the Founder, Chairman and CEO of ANEW. "Jeff has over 20 years of experience in managing financial ope
SC 13G - ANEW Medical, Inc. (0001907223) (Subject)
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company") (NASDAQ:WENA) announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke ("TTS") regarding Nanoject, a needle-free, freeze-dried nanopowder autoinjector for medicines and vaccines. Needle phobia and injection or blood-drawing anxiety are prevalent among adults and children, creating barriers to adhering to doctor visits and medication protocols. Alternatives to needle/syringes have been introduced including creams, patches, inhalers, liquid autoinjectors, but they have significant cost and formulation limitations for topical applications. Th